Hi kens. I think it is important to note that increase of new patients from Q4 to Q1 despite being a seasonly weaker quarter in conjunction with the improved discountuation rates means we might see a figure higher than that. For example if we could expect 4% patient growth (quarter on quarter) that's closer to 17% increase over a year due to compounding affect. I don't know if we'll hit 4% relative increase each quarter, but I would think 15% may be achievable with the 30% increase in sales force and the more stable existing cohort of patients.
- Forums
- ASX - By Stock
- NEU
- Ann: DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.67%
!
$12.08

Ann: DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024, page-32
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.08 |
Change
-0.460(3.67%) |
Mkt cap ! $1.507B |
Open | High | Low | Value | Volume |
$12.45 | $12.45 | $11.88 | $1.748M | 145.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 281 | $12.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.08 | 438 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 8 | 12.050 |
2 | 304 | 12.040 |
4 | 492 | 12.030 |
4 | 594 | 12.020 |
6 | 1345 | 12.010 |
Price($) | Vol. | No. |
---|---|---|
12.060 | 146 | 1 |
12.070 | 258 | 3 |
12.080 | 590 | 4 |
12.090 | 1317 | 5 |
12.100 | 1642 | 7 |
Last trade - 10.54am 23/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |